Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer (1978)

Peer-Reviewed Study · Ewan Cameron and Linus Pauling · September 1978

Ewan Cameron, 1978-09: Follow-up analysis of 100 ascorbate-treated terminal patients and 1000 matched controls, measuring survival from first hospital attendance as well as from the point of 'untreatability'. It reports 22% of treated patients surviving more than one year versus 0.4% of controls.

The ascorbate-treated patients were found to have a mean survival time about 300 days greater than that of the controls.

Abstract (article pp. 4538-4542)

Ewan Cameron, 1978-09: Follow-up analysis of 100 ascorbate-treated terminal patients and 1000 matched controls, measuring survival from first hospital attendance as well as from the point of 'untreatability'. It reports 22% of treated patients surviving more than one year versus 0.4% of controls. Same design limits as CHF-10: matched historical controls, not randomised. Funder: not stated in the abstract. Comparator: matched controls from the same hospital population. Conflicts: Pauling was campaigning for vitamin C at the time; no disclosure statement. This is the paper the Mayo group set out to test prospectively (CHF-12, CHF-13). Study type: controlled study.